Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: LEE011|DRUG: Letrozole|DRUG: BYL719
Sponsor: Novartis Pharmaceuticals